



Published in final edited form as:

*Cancer Epidemiol Biomarkers Prev.* 2012 July ; 21(7): 1156–1166. doi:10.1158/1055-9965.EPI-12-0066.

## Common Breast Cancer Susceptibility Variants in *LSP1* and *RAD51L1* Are Associated with Mammographic Density Measures that Predict Breast Cancer Risk

Celine M. Vachon, Christopher G. Scott, Peter A. Fasching, Per Hall, Rulla M. Tamimi, Jingmei Li, Jennifer Stone, Carmel Apicella, Fabrice Odefrey, Gretchen L. Gierach, Sebastian M. Jud, Katharina Heusinger, Matthias W. Beckmann, Marina Pollan, Pablo Fernández-Navarro, Anna González-Neira, Javier Benítez, Carla H. van Gils, Mariëtte Lokate, N. Charlotte Onland-Moret, Petra H.M. Peeters, Judith Brown, Jean Leyland, Jajini S. Varghese, Douglas F. Easton, Deborah J. Thompson, Robert N. Luben, Ruth ML Warren, Nicholas J. Wareham, Ruth JF Loos, Kay-Tee Khaw, Giske Ursin, Eunjung Lee, Simon A. Gayther, Susan J. Ramus, Rosalind A. Eeles, Martin O. Leach, Gek Kwan-Lim for the UK study of MRI screening for breast cancer in women at high risk (MARIBS), Fergus J. Couch, Graham G. Giles, Laura Baglietto, Kavitha Krishnan, Melissa C. Southey, Loic Le Marchand, Laurence N. Kolonel, Christy Woolcott, Gertraud Maskarinec, Christopher A Haiman, Kate Walker, Nichola Johnson, Valerie A. McCormack, Margarethe Biong, Grethe I.G. Alnæs, Inger Torhild Gram, Vessela N. Kristensen, Anne-Lise Børresen-Dale, Sara Lindström, Susan E. Hankinson, David J. Hunter, Irene L. Andrulis, Julia A. Knight, Norman F. Boyd, Jonine D. Figueroa, Jolanta Lissowska, Ewa Wesolowska, Beata Peplonska, Agnieszka Bukowska, Edyta Reszka, JianJun Liu, Louise Eriksson, Kamila Czene, Tina Audley, Anna H. Wu, V. Shane Pankratz, John L. Hopper, and Isabel dos-Santos-Silva

John L. Hopper, Jennifer Stone and Carmel Apicella, University of Melbourne, School of Population Health, Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, Melbourne, Australia; Fabrice Odefrey, University of Melbourne, Department of Pathology, Melbourne, Australia

Peter A. Fasching, University of California at Los Angeles, Department of Medicine, Division of Hematology and Oncology, Dafid Geffen School of Medicine, USA; Sebastian M. Jud, Katharina Heusinger and Matthias W. Beckmann, University Breast Center Franconia, Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Germany

Marina Pollan and Pablo Fernández-Navarro, Área de Epidemiología Ambiental y Cáncer, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain, and Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública CIBERESP), Madrid, Spain; Anna González-Neira and Javier Benítez, Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain

---

Corresponding Author: Celine M. Vachon, PhD, Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, vachon@mayo.edu, tel: 507-284-9977, fax: 507-266-2478; Isabel dos-Santos-Silva, MD, PhD, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, UK, isabel.silva@lshtm.ac.uk, tel: +44 (0)20 7927 2113, fax: +44 (0)20 7436 4230.

### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Carla H. van Gils, Mariëtte Lokate, N. Charlotte Onland-Moret, and Petra H.M. Peeters, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands

Judith Brown, Jean Leyland, Jajini Varghese, Douglas F Easton, Deborah J Thompson, and Robert N Luben, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; Ruth ML Warren, Department of Radiology, University of Cambridge, Addenbrooke's NHS Foundation Trust Cambridge, UK; Nick J Wareham and Ruth JF Loos, MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK; K-T Khaw, MRC Centre for Nutritional Epidemiology in Cancer Prevention and Survival (CNC), University of Cambridge, Cambridge, UK

Giske Ursin, Cancer Registry of Norway, Oslo, Norway; Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Norway, and Department of Preventive Medicine, Keck School of Medicine, University of Southern California, USA; Eunjung Lee, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, USA

Deborah J Thompson, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; Ruth ML Warren, Department of Radiology, University of Cambridge, Addenbrooke's NHS Foundation Trust Cambridge, UK; Simon Gayther and Susan J Ramus, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA; Rosalind Eeles, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK; Martin O Leach, and Gek Kwan-Lim, CR-UK and EPSRC Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK, for the UK study of MRI screening for breast cancer in women at high risk (MARIBS)

Celine M. Vachon, Christopher G. Scott, V. Shane Pankratz, Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA; Fergus J. Couch, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA

Graham G. Giles and Laura Baglietto, Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia, and Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Melbourne, Australia; Kavitha Krishnan, Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia; Melissa C. Southey, Department of Pathology, University of Melbourne, Melbourne, Australia

Loic Le Marchand, Laurence N Kolonel, Christy Woolcott, Gertraud Maskarinec, University of Hawaii Cancer Center, Honolulu, HI 96813, USA; Christopher Haiman, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA

Isabel dos-Santos-Silva and Kate Walker, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, UK; Nichola Johnson, Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK; Valerie McCormack, Section of Environment and Radiation, International Agency for Research on Cancer, Lyon 69008, France

Margarethe Biong, Grethe I.G. Alnæs, Vessela N. Kristensen, and Anne-Lise Børresen-Dale, Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello 0310, Oslo, Norway; Inger Torhild Gram, Institute of Community Medicine, Faculty of Health Sciences, University of Tromsø, Norway

Rulla M. Tamimi and Susan E Hankinson, Channing Laboratory, Brigham and Women's Hospital, Boston, MA 02115, USA, and Department of Epidemiology, Harvard School of Public Health, Boston, MA, 02115; Sara Lindström and David J Hunter, Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Harvard School of Public Health, Boston, MA, 02115, USA

Irene L. Andrulis, Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, and Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada; Julia A. Knight, Prosserman Centre for Health Research, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada, and Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada; Norman F. Boyd, Campbell Family Institute for Breast Cancer Research, Ontario Cancer Institute, Toronto, Ontario, Canada

Gretchen L. Gierach and Jonine D. Figueroa, Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA; Jola Lissowska and Ewa Wesolowska, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

Beata Peplonska, Agnieszka Bukowska, MSc, Department of Environmental Epidemiology, Nofer Institute of Occupational Medicine, Lodz, Poland; Edyta Reszka, Department of Toxicology and Carcinogenesis Nofer Institute of Occupational Medicine, Lodz, Poland; Giske Ursin, Cancer Registry of Norway, Oslo, Norway and Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway, and Department of Preventive Medicine, Keck School of Medicine, University of Southern California, CA 90089, USA

Jingmei Li, Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden, and Human Genetics, Genome Institute of Singapore, Singapore; JianJun Liu, Human Genetics, Genome Institute of Singapore, Singapore; Louise Eriksson, Kamila Czene and Per Hall, Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden

Jajini Varghese, Douglas F Easton, Deborah J Thompson, Tina Audley, Judith Brown and Jean Leyland, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; Ruth ML Warren, Department of Radiology, University of Cambridge, Addenbrooke's NHS Foundation Trust Cambridge, UK

Anna H. Wu, Professor of Preventive Medicine, University of Southern California, 1441 Eastlake Avenue, MC 9175, Los Angeles, CA 90089

## Abstract

**Background**—Mammographic density adjusted for age and body mass index (BMI) is a heritable marker of breast cancer susceptibility. Little is known about the biological mechanisms underlying the association between mammographic density and breast cancer risk. We examined whether common low-penetrance breast cancer susceptibility variants contribute to inter-individual differences in mammographic density measures.

**Methods**—We established an international consortium (DENSENP) of 19 studies from 10 countries, comprising 16,895 Caucasian women, to conduct a pooled cross-sectional analysis of common breast cancer susceptibility variants in 14 independent loci and mammographic density measures. Dense and non-dense areas, and percent density, were measured using interactive-thresholding techniques. Mixed linear models were used to assess the association between genetic variants and the square roots of mammographic density measures adjusted for study, age, case status, body mass index (BMI) and menopausal status.

**Results**—Consistent with their breast cancer associations, the C-allele of rs3817198 in *LSP1* was positively associated with both adjusted dense area ( $p=0.00005$ ) and adjusted percent density ( $p=0.001$ ) whereas the A-allele of rs10483813 in *RAD51L1* was inversely associated with adjusted percent density ( $p=0.003$ ), but not with adjusted dense area ( $p=0.07$ ).

**Conclusion**—We identified two common breast cancer susceptibility variants associated with mammographic measures of radio-dense tissue in the breast gland.

**Impact**—We examined the association of 14 established breast cancer susceptibility loci with mammographic density phenotypes within a large genetic consortium and identified two breast cancer susceptibility variants, *LSP1*-rs3817198 and *RAD51L1*-rs10483813, associated with mammographic measures and in the same direction as the breast cancer association.

## Keywords

breast density; breast cancer; genetics; biomarkers; mammography

## Introduction

Genetic factors play a major role in the pathogenesis of breast cancer (1-3). Recent multi-stage genome-wide association studies (GWAS) and candidate gene studies conducted by several groups, including the Breast Cancer Association Consortium (BCAC), have successfully identified and replicated associations between over 18 single nucleotide polymorphisms (SNPs) and risk of breast cancer in Caucasians (4-9).

Mammographic density, which reflects variations in the amounts of fat, stromal and epithelial tissues in the breast, is one of the strongest risk factors for breast cancer with risk being 4-6 fold higher for women in the highest relative to lowest density categories after adjusting for age and body mass index (BMI) (10, 11). The biology underlying the mammographic density and breast cancer association is essentially unknown, but twin and family studies suggest that additive genetic factors explain ~60% of variance in the density measures (12, 13). This raises the question of whether breast cancer susceptibility variants identified to date are associated with mammographic density measures. This could lead to new insights into the etiology of breast cancer by revealing the biological reasons for these associations with breast cancer risk (14).

Five studies have examined the association of breast cancer susceptibility SNPs with age and BMI adjusted measures of mammographic density (14-18). The most consistent finding was an association between [lymphocyte-specific protein-1, *LSP1*]-rs3817198 and adjusted dense area and percent density, in the same direction as the association with breast cancer. The association was observed overall by Odefrey et al (17) but only in specific subgroups by others: in premenopausal women (14), current users of postmenopausal hormones (PMH), (15) or ER+/PR+ cases only (16). Other nominally significant reported SNP-density associations consistent with the association of these SNPs with breast cancer risk include associations of *TOX3*-rs12443621 (14, 15) and rs4666451 (14) with adjusted percent density, in pre-menopausal women only, and rs13281615 at 8q24 with both adjusted percent density and dense area (17). The largest study to date, a meta-analysis of five GWAS of mammographic density involving 4877 women with and without breast cancer, identified a genome-wide significant association between *ZNF365*- rs10995190, a known breast cancer susceptibility SNP, and adjusted percent density as well as weak evidence of possible associations with *ESR1*-rs2046210 (p=0.005) and *LSP1*-rs3817198 (p=0.04) (18).

Only one previous study (17), however, examined the SNP associations with the components that comprise the percent density phenotype, namely dense area and non-dense area. Dense area has been hypothesized to be the more relevant density phenotype for understanding the etiology of mammographic density (19) as tumors have been shown to arise within the radiodense tissue (20). Whether these SNPs influence dense and/or non-dense area could help to interpret the mechanism by which the loci influence density and possibly cancer.

We established an international collaboration - the DENSNP consortium - of studies with data on established breast cancer susceptibility variants and quantitative density measures

from film mammography to conduct analyses of breast cancer susceptibility SNPs in relation to the three density phenotypes. This paper reports the findings for 15 breast cancer SNPs at 14 loci, identified through 2009 when the DENSNP consortium was established.

## Materials and Methods

### Study samples

The DENSNP consortium comprises 19 studies from Europe, North America and Australia with the present analyses restricted to Caucasian women. Individual studies, their design and sample sizes are described in Supplemental Table 1. Covariate data, including age, reproductive variables and exogenous hormone use, were obtained through self-administered postal questionnaires (12 studies), in-person interviews (six studies) or telephone interviews (one study) (Supplemental Table 2). Participants' weights, heights and hence BMIs were measured by trained staff (10 studies) and self-reported (nine studies). For eight studies, there was an average six months or less between mammography and collection of participant information; for 18, the average was three years or less

Each study obtained informed consent and relevant ethics and institutional approvals. Only anonymised data were made available to the DENSNP consortium.

### Digitization and density measures

All studies obtained film mammograms - either the mediolateral oblique (MLO) (7 studies) or cranio-caudal (CC) (12 studies) views - for participants, including breast cancer cases and/or non-cases, except PNS which digitized copies of digital mammograms (Supplemental Table 3). For cases, the film from the unaffected contralateral breast taken at the time of cancer diagnosis was used, except for three nested case-control studies for which images obtained prior to diagnosis were used (two studies used average measurements of the both breasts; one study used only the right breast). For non-cases, both breasts (averaged), left or right only, or the side that corresponded to the matched case was chosen.

As a requirement for entry, participating studies contributed percent density, dense area and non-dense area measures for cases and/or non-cases using one of two similar semi-automated methods that rely on the interactive threshold technique, Cumulus (21) and Madena (22) softwares. Both require an interactive selection of two grayscale thresholds in the image of a digitized mammogram by a trained observer. One threshold separates the breast from the background and the other classifies the breast tissue into dense and non-dense areas, from which percent density ( $100 \times \text{dense area} / \text{total breast area}$ ) and absolute measures of dense and non-dense areas are automatically generated. Images were anonymised and readers were blind to the genotype, case status (if applicable) and risk factor data.

### Genotyping and quality control

SNPs confirmed to be associated with breast cancer susceptibility in the 14 regions (loci) of the genes *FGFR2*, *LSP1*, *MAP3K1*, *TOX3*, *SLC4A7/NEK10*, *COX11*, *CASP8*, *TGFB1*, *RAD51L1*, *ESR1*, *MRPS30/FGF10* and positions 8q24.21, 2q35 and 1p11.2 were measured (Figure 1). These loci were identified by GWAS (4-7) except *CASP8* and *TGFB1* which were identified using the candidate gene approach (8). For the *CASP8* locus there were alternate SNPs (rs1045485 and rs17468277) available in strong linkage disequilibrium or LD ( $r^2=0.98$ ). The rs1045485 SNP was used if available; if not rs17468277 was used. For the 2275 women with genotypes for both SNPs, these were concordant for all but 9 samples, so were used interchangeably. Two SNPs were also available for each of the *RAD51L1* (rs10483813 and rs999737) and *MRPS30/FGF10* (rs4415048 and rs10941679) loci. The



SNPs in MRPS30/FGF10 were not in strong disequilibrium ( $r^2 < 0.6$  in our dataset) and are reported separately. Rs10483813 and rs999737 (*RAD51L1*) were in high LD ( $r^2 = 0.98$  in our dataset), but studies had either genotyped both SNPs, or only rs10483813; thus, we only report results for rs10483813 for which we had a larger sample size.

Genotyping was performed on various platforms by the individual studies (Supplemental Table 4). Quality control was conducted at the study level; all SNP call rates were  $>90\%$ , with few (10 SNPs from five studies)  $<95\%$ . Three SNPs (from three studies) with Hardy Weinberg Equilibrium p-values  $<0.001$  were excluded. The number of SNPs genotyped by each study varied from all 14 (four studies) to only two (two studies), with a median of 10 per study.

## Statistical methods

Study-specific data were checked to ensure that the coding and scaling of each variable were similar across studies. For the AMTDSS, one twin was selected at random from the 563 monozygous pairs. Examination of the distributions of residuals of density phenotypes adjusted for age, BMI, and menopausal status showed that a square root transformation of all density variables gave a good approximation to a normal distribution and this was used in all analyses.

A test of the null hypothesis of no association between any of the tested SNPs and a given mammographic measure was performed using Fisher's method (23). As individual-level data were available from all studies, primary analyses used a mixed model approach that included per-study random effects to capture study-specific differences. When applicable, a repeated measures adjustment within families assuming a compound symmetry correlation structure was used to account for familial correlation. Models were adjusted for the fixed effects of age (continuous), BMI (1/BMI, was used as it provided a better fit), case status and menopausal status (pre- and peri- combined vs. post, with the latter defined as no menstruation for 12 or more months, not due to pregnancy). A missing category was included, when applicable. Primary analyses considered SNP associations as additive genetic effects, by defining an ordinal covariate as the number of copies of the minor allele carried by the study subjects and fitted a linear association. The resulting estimate of the per-allele effect is reported as the "additive estimate" in the tables. Estimates of the adjusted mean mammographic density measures and their 95% confidence intervals (95% CI), corresponding to the observed genotypes of each variant, were derived by back-transformation from the square-root to the original scale. Additional analyses were performed within subsets of women defined by menopause categories (pre- and perimenopausal combined vs. postmenopausal), BMI ( $<$  vs. median of  $25 \text{ kg/m}^2$ ), PMH (ever vs. never use), and case status to assess whether SNP-density phenotype associations were modified by these variables.

Between-study heterogeneity was tested by fitting study-by-genotype interactions. Analyses were performed using SAS version 9.2 (SAS Institute, Inc., Cary, NC). Two sided p-values were calculated. A Bonferroni adjustment to account for multiple testing was applied to define the threshold for statistical significance as  $p = 0.003 (=0.05/14 \text{ loci})$ .

## Results

There were 5,110 breast cancer cases and 11,785 non-cases of self-reported Caucasian race/ethnicity with available density phenotypes, risk factors and at least one of the 15 SNPs considered [Table 1]. The number of participants varied by SNP with the most comprehensive information for 2q35 ( $n=13,254$ ), *CASP8* ( $n=12,816$ ) and *FGFR2*

(n=12,680), and least information for *TGFBI* (n=3,099), *RAD51LI* (n=7,610) and *ESRI* (n=8,274).

The majority of the participants were aged  $\geq 40$  years (98%) and postmenopausal (77%), and approximately half of those aged  $\geq 55$  reported ever using PMH (48%) [Table 1]. In all, 44% of participants had a BMI  $< 25$  kg/m<sup>2</sup> [Table 1]. A small proportion was nulliparous (11%), precluding subgroup analyses by parity. The associations between these variables and the three density phenotypes are shown in Table 2, and were similar to those reported in the literature.

The results from our primary analyses of the 15 SNPs in 14 breast cancer loci with the three density phenotypes are shown in Figure 1 and described in Supplemental Tables 5a-c. Pictured are the parameter estimates from the mixed linear models corresponding to each genotype. There was strong evidence against the null hypothesis that none of the SNPs were associated with both the dense area ( $p < 0.001$ ) and percent density measures ( $p = 0.001$ ), but not with the non-dense area measure ( $p = 0.5$ ). This suggests that at least one of the 14 breast loci is associated with the density or dense area measures.

The strongest associations were seen with rs3817198 (*LSP1*) and the dense area ( $p = 0.00005$ ) and percent density ( $p = 0.001$ ) phenotypes with little evidence for between-study heterogeneity [Figure 2]. The adjusted mean dense area was 23.7cm<sup>2</sup> for T/T carriers, 25.1cm<sup>2</sup> for T/C carriers and 26.0cm<sup>2</sup> for C/C carriers (Supplemental Table 5a-b). The adjusted mean percent density for T/T carriers was 19.4% compared to 20.1% for T/C and 20.5% for C/C carriers, respectively. These associations were consistent across studies [Figure 2] and persisted after exclusion of studies that had previously reported on *LSP1* and density, namely NHS, AMDTSS, LIFE, MEC, EPIC-Norfolk I and SASBAC(14-18) (e.g.  $p = 0.004$  for dense area). There was also evidence of an inverse association between rs10483813 (*RAD51LI*) and adjusted percent density ( $p = 0.003$ ), but not with adjusted dense area ( $p = 0.07$ ) [Figure 1]. These associations were consistent across studies [Figure 2] with the adjusted mean percent density for T/T genotype being 21.1%, compared to 20.5% for T/C and 19.0% for A/A.

There were nominal associations of adjusted percent density and dense area with rs2046210 (*ESRI*), rs1045485/rs17468277 (*CASP8*), rs4973768 (*SLC44A7/NEK10*) and rs3803662 (*TOX3*) [Supplemental Tables 5a-b] which were in the direction of the published corresponding breast cancer associations but not statistically significant after taking into account multiple testing [Figure 1]. None of the investigated SNPs were associated with non-dense area [Figure 1; Supplemental Table 5c].

The genetic associations above did not diminish after further adjustment for parity or view (data not shown) and, in general, did not appear to differ by case status, BMI, menopausal status, or PMH use [Supplemental Tables 6a-c] but the study had low power to examine interactions.

We also examined the association of these SNPs with breast cancer risk before and after adjustment for the density measures by pooling data from studies that recruited both cases and non-cases [identified in Supplemental Table 1]. Using 3,175 cases and 6,504 non-cases from eight studies, the per C-allele odds ratio (OR) for rs3817198 (*LSP1*) was 1.04 (95% CI 0.97, 1.12) without adjustment for either density measure. When including dense area as a covariate, the OR was 1.03 (95% CI 0.96, 1.10), and after adjustment for percent density instead, the OR was 1.02 (95% CI 0.95, 1.11). Similarly, using 2,765 cases and 3,022 non-cases from four studies, the per A-allele OR for rs10483813 (*RAD51LI*) was 0.92 (95% CI 0.84, 1.00) without adjustment for either density measure, 0.93 (95% CI 0.85, 1.01) after adjustment for dense area, and 0.94 (95% CI 0.86, 1.03) after adjustment for percent density.

## Discussion

There is wide inter-individual variability in mammographic density measures, but known epidemiologic risk factors account for only 20-30% variability in percent density (13, 24, 25). We hypothesized that common low-penetrance breast cancer susceptibility variants contribute to the remaining inter-individual differences in the density phenotypes and examined this within a large international consortium (DENSENP). Here, we report the first findings from this collaborative effort and identify associations between adjusted measures of density and two breast cancer susceptibility SNPs, rs3817198 (*LSP1*) and rs10483813 (*RAD51L1*), which were in the same direction as the corresponding SNP associations with cancer risk.

The most marked association with density was with rs3817198 (*LSP1*). We also confirmed this association using the 10 studies that had not previously published on the *LSP1* variant and density association, providing consistent evidence for this mammographic density locus. The mechanisms through which this SNP (or more likely the causal allele(s) it tags) may affect density and cancer risk are unclear. The *LSP1* gene encodes an intracellular F-actin binding protein, which is expressed in lymphocytes, neutrophils, and endothelium and might regulate neutrophil motility, adhesion to fibrinogen matrix proteins, and transendothelial migration (26).

The SNP rs3817198 in *RAD51L1*, a gene on chromosome 14q24.1 involved in the double-strand DNA-repair and homologous-recombination pathway, may also be associated with the adjusted density measures, although the evidence is less compelling than for rs3817198 (*LSP1*). The biological mechanisms underlying the possible association of this variant with density and cancer risk are unknown. *RAD51L1* interacts with *RAD51*, and a SNP in the 5'UTR of *RAD51* has been found to be associated with breast cancer risk for *BRCA2* mutation carriers (27). However, mutations in *BRCA1* and *BRCA2* have not been found to be associated with the density phenotypes (28, 29).

Several breast cancer GWAS have consistently identified polymorphisms in intron 2 of fibroblast growth factor receptor 2 (*FGFR2*), with each copy of the T allele of rs2981582 being associated with about a 26% increased breast cancer risk (30). Our study had 90% power to detect an average difference in percent density of less than 1% between homozygote carriers and non-carriers of this SNP, if such a difference truly exists, and therefore the lack of finding an association suggests that density is unlikely to mediate the association between *FGFR2* and breast cancer risk. Similar considerations apply to SNPs in several other breast cancer loci, including TOX3-rs3803662, 2q35-rs13387042 and MAP3K1-rs889312. These loci are likely to contribute independently of density to risk prediction. In fact, when we added *LSP1*-rs3817198 and *RAD51L1*-rs10483813 to a risk model with age, BMI, menopause, study and percent density the inclusion of these two SNPs did not affect the AUC whereas the addition of the remaining 12 SNPs increased the AUC from 0.62 to 0.65 ( $p < 0.001$ ).

Previous studies were based on smaller sample sizes (ranging from 578 (16) to 4,877 (18)), which could have precluded the detection of small effects. Our study is the largest conducted so far with sample sizes greater than 6,000 for all but one SNP and greater than 10,000 for all but 5 SNPs. We had over 90% power to detect per-allele differences in adjusted percent density of 1% or less for all but three SNPs (rs17468277, rs10483813 and rs4415084), and even for these SNPs, we were similarly powered to detect per-allele differences of less than 2%. However, limited power precluded a more detailed examination of interactions with BMI (e.g. differential SNP effects in BMI-defined quartiles) and PMH use (e.g. different



SNP effects by type of PMH, recency of use). The study also had low power to assess the mediation of the SNP and breast cancer associations by density.

The mammographic density readings were performed in different sets of films (e.g. left, right or both breasts; CC or MLO views), but it is unlikely that this may have affected substantially our findings because there is a high correlation between a woman's density measurements taken from the various breast-view combinations(31). For cases, both pre-diagnostic films and films from the unaffected breast at the time of diagnosis, but prior to treatment, were used - an approach used by others (10); furthermore, our findings were not modified by case status. One small study (PNS) used digitized copies of digital mammograms, but its exclusion did not affect the results shown here. Although mammographic density readings were not standardized, all studies used a similar interactive-threshold approach and had very high within- and between-observer repeatability (typically >90%) (32). Also, all analyses were adjusted for study hence minimizing the impact of any between-study differences on density measurements which would have likely reduced our power to detect real associations. Reassuringly, we were able to reproduce the well-established influences of age, BMI, parity, menopausal status and PMH on density phenotypes within each one of the participating studies as well as in joint analyses.

Our findings suggest that two of 14 well-established breast cancer loci may contribute to the large between-woman differences in risk-predicting density phenotypes, consistent with estimates of 5-10% genetic overlap between this biomarker and breast cancer (33). The two common variants in *LSP1* and *RAD51L1* explained 0.2% (combined, 0.1% for each) of the variance in adjusted percent density and dense area, although the overall contribution could be larger if the true causal variants are more strongly associated with density than the tagging SNPs we examined here. At the individual level, these SNPs were associated with a 0.6% absolute increase in percent density per allele for *LSP1* and 0.8% absolute decrease in percent density per allele for *RAD51L1*. These magnitudes can be compared with, for example, the change in density measures of 1% decrease per year of ageing (34), 2% increase with use of PMH and 2% decrease over the menopausal transition (35). Our findings are consistent with the hypothesis that mammographic density is likely a polygenic trait, influenced by many common low-penetrance variants, and/or rarer variants with larger effects which cannot be identified through current GWAS. Identification of such variants, and clarification of their role and function, is likely to improve our understanding of the biology of mammographic density and how this phenotype is associated with breast cancer risk.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

### Grant Support

**AMDTSS:** This research was facilitated through access to the Australian Twin Registry, a national resource supported by an Enabling Grant (ID 628911) from the National Health and Medical Research Council (NHMRC), and supported by grants from the NHMRC and National Breast Cancer Foundation/Cancer Australia. JLH is an Australian Fellow of the NHMRC and a Victorian Breast Cancer Research Consortium (VBCRC) Group Leader. We thank the twins and sisters who participated in this study.

**BBCC:** This study was funded in part by the ELAN-Program of the University Hospital Erlangen; Katharina Heusinger was funded by the ELAN program of the University Hospital Erlangen.

**DDM-Spain:** This study was supported by Research Grant FIS PI060386 from Spain's Health Research Fund (Fondo de Investigacio'n Sanitaria); the EPY 1306/06 Collaboration Agreement between Astra-Zeneca and the Instituto de Salud Carlos III; and a grant from the Spanish Federation of Breast Cancer (FECMA).

**EPIC-NL:** This study was funded by "Europe against Cancer" Programme of the European Commission (SANCO), Dutch Ministry of Health, Dutch Cancer Society, ZonMW the Netherlands Organisation for Health Research and Development, and the World Cancer Research Fund (WCRF).

**EPIC-Norfolk I:** This study was funded by research programme grant funding from Cancer Research UK and the Medical Research Council with additional support from the Stroke Association, British Heart Foundation, Department of Health, Research into Ageing and Academy of Medical Sciences.

**EPIC-Norfolk II:** This study was funded by Cancer Research UK.

**LIFE:** This study was supported by grants CA17054 and CA74847 from the National Cancer Institute, National Institutes of Health, 4PB-0092 from the California Breast Cancer Research Program of the University of California, and in part through contract no. N01-PC-35139, and T32 ES-013678 from the National Institute of Environmental Health Sciences, National Institute of Health. The collection of cancer incidence data used in this publication was supported by the California Department of Health Services as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. The ideas and opinions expressed herein are those of the authors, and no endorsement by the State of California, Department of Health Services is intended or should be inferred.

**MARIBS:** This study was funded by a Cancer Research UK project grant (C11518/A5644). The genetic studies were funded by Cancer Research UK as a separate project grant (C5047/A5830). The main MARIBS study was supported by a grant from the UK Medical Research Council (G9600413). SJR was funded by the Mermaid arm of the Eve Appeal.

**MCBCS:** This study was supported by Public Health Service Grants P50 CA 116201, R01 CA 128931, R01 CA 128931-S01, R01 CA 122340 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.

**MCCS:** Melissa C. Southey is a National Health and Medical Research Council Senior Research Fellow and a Victorian Breast Cancer Research Consortium Group Leader. The study was supported by the Cancer Council of Victoria and by the Victorian Breast Cancer Research Consortium

**MEC:** National Cancer Institute: R37CA054281, R01CA063464, R01CA085265, R25CA090956, R01CA132839.

**MOG:** This study was supported programme and project grants from Cancer Research UK and Breast Cancer Campaign. We acknowledge NHS funding to the NIHR Royal Marsden Biomedical Research Centre.

**NBCS:** This study has been supported with grants to VNK(Vessela N. Kristensen) and ALBD(Anne-Lise Børresen-Dale) from Norwegian Research Council (#183621/S10 and #175240/S10), The Norwegian Cancer Society (PK80108002, PK60287003), and The Radium Hospital Foundation as well as S-02036 from South Eastern Norway Regional Health Authority.

**NHS:** This study was supported by Public Health Service Grants CA131332, CA087969, CA089393, CA049449, CA98233, CA128931, CA 116201, CA 122340 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.

**OFBCR:** This work was supported by the US National Cancer Institute, National Institutes of Health under RFA # CA- 06-503 (Cancer Care Ontario U01 CA69467) and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR) and Principal Investigators. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR.

**PBCS:** This study was supported by the Intramural Research Program of the U.S. National Cancer Institute, Department of Health and Human Services, USA. The PBCS would like to thank Pei Chao and Michael Stagner from Information Management Services (Silver Spring, MD) for data management support; Laurie Burdette, Amy Hutchinson, and Jeff Yuenger from the NCI Core Genotyping facility for genotyping support; the participants, physicians, pathologists, nurses, and interviewers from participating centers in Poland for their efforts during field-work; Dr. Norman Boyd from the University of Toronto for providing the mammographic density assessments; and Drs. Louise Brinton, Montserrat Garcia-Closas, Beata Peplonska, and Mark Sherman for their contributions to the study design.

**PNS:** The project was supported by a grant from Norway through the Polish - Norwegian Research Fund (PNRF – 243 – AI – 1/07)


**SASBAC:** The SASBAC study was supported by Märıt and Hans Rausing’s Initiative against Breast Cancer, National Institutes of Health, Susan Komen Foundation and Agency for Science, Technology and Research of Singapore (A\*STAR).

**SIBS:** SIBS was supported by a programme grant and project grants from Cancer Research UK. Douglas F Easton is a Principal Research Fellow of Cancer Research UK.

## References


1. Nathanson KL, Wooster R, Weber BL. Breast cancer genetics: what we know and what we need. *Nat Med.* 2001; 7:552–6. [PubMed: 11329055]
2. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. *Cancer Epidemiol Biomarkers Prev.* 1999; 8:843–54. [PubMed: 10548311]
3. Coughlin SS, Piper M. Genetic polymorphisms and risk of breast cancer. *Cancer Epidemiol Biomarkers Prev.* 1999; 8:1023–32. [PubMed: 10566559]
4. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature.* 2007; 447:1087–93. [PubMed: 17529967]
5. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson GF, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat Genet.* 2008; 40:703–6. [PubMed: 18438407]
6. Ahmed S, Thomas G, Ghousaini M, Healey CS, Humphreys MK, Platte R, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. *Nat Genet.* 2009; 41:585–90. [PubMed: 19330027]
7. Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). *Nat Genet.* 2009; 41:579–84. [PubMed: 19330030]
8. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, et al. A common coding variant in CASP8 is associated with breast cancer risk. *Nat Genet.* 2007; 39:352–8. [PubMed: 17293864]
9. Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. *Nat Genet.* 2009; 41:324–8. [PubMed: 19219042]
10. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. *Cancer Epidemiol Biomarkers Prev.* 2006; 15:1159–69. [PubMed: 16775176]
11. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. *N Engl J Med.* 2007; 356:227–36. [PubMed: 17229950]
12. Stone J, Dite GS, Gunasekara A, English DR, McCredie MR, Giles GG, et al. The heritability of mammographically dense and nondense breast tissue. *Cancer Epidemiol Biomarkers Prev.* 2006; 15:612–7. [PubMed: 16614099]
13. Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR, et al. Heritability of mammographic density, a risk factor for breast cancer. *N Engl J Med.* 2002; 347:886–94. [PubMed: 12239257]
14. Tamimi RM, Cox D, Kraft P, Colditz GA, Hankinson SE, Hunter DJ. Breast cancer susceptibility loci and mammographic density. *Breast Cancer Res.* 2008; 10:R66. [PubMed: 18681954]
15. Woolcott CG, Maskarinec G, Haiman CA, Verheus M, Pagano IS, Le Marchand L, et al. Association between breast cancer susceptibility loci and mammographic density: the Multiethnic Cohort. *Breast Cancer Res.* 2009; 11:R10. [PubMed: 19232126]
16. Lee E, Haiman CA, Ma H, Van Den Berg D, Bernstein L, Ursin G. The role of established breast cancer susceptibility loci in mammographic density in young women. *Cancer Epidemiol Biomarkers Prev.* 2008; 17:258–60. [PubMed: 18199735]

17. Odefrey F, Stone J, Gurrin LC, Byrnes GB, Apicella C, Dite GS, et al. Common genetic variants associated with breast cancer and mammographic density measures that predict disease. *Cancer Res.* 2010; 70:1449–58. [PubMed: 20145138]
18. Lindstrom S, Vachon CM, Li J, Varghese J, Thompson D, Warren R, et al. Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. *Nat Genet.* 2011; 43:185–7. [PubMed: 21278746]
19. Haars G, van Noord PA, van Gils CH, Grobbee DE, Peeters PH. Measurements of breast density: no ratio for a ratio. *Cancer Epidemiol Biomarkers Prev.* 2005; 14:2634–40. [PubMed: 16284389]
20. Pereira SM, McCormack VA, Hipwell JH, Record C, Wilkinson LS, Moss SM, et al. Localized fibroglandular tissue as a predictor of future tumor location within the breast. *Cancer Epidemiol Biomarkers Prev.* 2011; 20:1718–25. [PubMed: 21693627]
21. Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. The quantitative analysis of mammographic densities. *Phys Med Biol.* 1994; 39:1629–38. [PubMed: 15551535]
22. Ursin G, Ma H, Wu AH, Bernstein L, Salane M, Parisky YR, et al. Mammographic density and breast cancer in three ethnic groups. *Cancer Epidemiol Biomarkers Prev.* 2003; 12:332–8. [PubMed: 12692108]
23. Fisher, R. *Statistical Methods for Research Workers.* 14. New York: Hafner/MacMillan; 1970.
24. Ursin G, Lillie EO, Lee E, Cockburn M, Schork NJ, Cozen W, et al. The relative importance of genetics and environment on mammographic density. *Cancer Epidemiol Biomarkers Prev.* 2009; 18:102–12. [PubMed: 19124487]
25. Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA. Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). *Cancer Causes Control.* 2000; 11:653–62. [PubMed: 10977110]
26. Lanigan F, O'Connor D, Martin F, Gallagher WM. Molecular links between mammary gland development and breast cancer. *Cell Mol Life Sci.* 2007; 64:3159–84. [PubMed: 17955178]
27. Antoniou AC, Sinilnikova OM, Simard J, Leone M, Dumont M, Neuhausen SL, et al. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. *Am J Hum Genet.* 2007; 81:1186–200. [PubMed: 17999359]
28. Mitchell G, Antoniou AC, Warren R, Peock S, Brown J, Davies R, et al. Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Res.* 2006; 66:1866–72. [PubMed: 16452249]
29. Gierach GL, Loud JT, Chow CK, Prindiville SA, Eng-Wong J, Soballe PW, et al. Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer. *Breast Cancer Res Treat.* 2010; 123:245–55. [PubMed: 20130984]
30. Udler MS, Meyer KB, Pooley KA, Karlins E, Struewing JP, Zhang J, et al. FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. *Hum Mol Genet.* 2009; 18:1692–703. [PubMed: 19223389]
31. McCormack VA, Highnam R, Perry N, dos Santos Silva I. Comparison of a new and existing method of mammographic density measurement: intramethod reliability and associations with known risk factors. *Cancer Epidemiol Biomarkers Prev.* 2007; 16:1148–54. [PubMed: 17548677]
32. Lee-Han H, Cooke G, Boyd NF. Quantitative evaluation of mammographic densities: a comparison of methods of assessment. *Eur J Cancer Prev.* 1995; 4:285–92. [PubMed: 7549820]
33. Martin LJ, Melnichouk O, Guo H, Chiarelli AM, Hislop TG, Yaffe MJ, et al. Family history, mammographic density, and risk of breast cancer. *Cancer Epidemiol Biomarkers Prev.* 2010; 19:456–63. [PubMed: 20142244]
34. Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, et al. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. *Ann Intern Med.* 1999; 130:262–9. [PubMed: 10068383]
35. McCormack VA, Perry NM, Vinnicombe SJ, Dos Santos Silva I. Changes and tracking of mammographic density in relation to Pike's model of breast tissue aging: a UK longitudinal study. *Int J Cancer.* 2010; 127:452–61. [PubMed: 19924817]



**Figure 1.**  
 Associations of common breast cancer susceptibility variants with adjusted percent mammographic density, dense area and non dense area





<sup>a</sup> Ordinal analyses on square root density measure adjusted for age, BMI, menopausal status, and case status.

<sup>b</sup> Size of square proportional to sample size.

<sup>c</sup> Pooled analyses additionally adjusted for study.

<sup>d</sup> P-value for between-study heterogeneity.

**Figure 2.**  
Study specific associations of rs3817198-*LSP1* and rs10483813-*RAD51L1* with adjusted percent mammographic density and dense area.

**Table 1**

Summary Characteristics of the 19 DENSNP Studies

Characteristic	Category	No. of studies	BC cases		Non-cases		Overall	
			N	%	N	%	N	%
Overall		19	5110	30	11785	70	16895	100
Study design								
	<i>Cohort</i>	3	16	0.3	1582	13	1598	9
	<i>Cross-sectional</i>	5	38	1	3064	26	3102	18
	<i>Case-control</i>	5	3280	64	2217	19	5497	33
	<i>Nested case-control</i>	3	1599	31	2099	18	3698	22
	<i>Family-based</i>	3	177	3	2823	24	3000	18
Source of demographic & reproductive data								
	<i>In-person interview</i>	6	1631	32	1276	11	2907	17
	<i>Postal questionnaire</i>	12	3378	66	8831	75	12209	72
	<i>Telephone interview</i>	1	101	2	1678	14	1779	11
Age (yrs) <sup>b</sup>								
	<i>&lt;40</i>	9	221	4	145	1	366	2
	<i>40-49</i>	17	937	18	1857	16	2794	17
	<i>50-59</i>	18	1643	32	4843	41	6486	38
	<i>60-69</i>	16	1659	32	4011	34	5670	34
	<i>70</i>	13	650	13	929	8	1579	9
Parity								
	<i>Nulliparous</i>	19	614	12	1167	10	1781	11
	<i>Parous</i>	19	4329	85	10479	89	14808	88
	<i>Unknown</i>	8	167	3	139	1	306	2
Menopausal status*								
	<i>Pre-menopausal</i>	16	1185	23	2241	19	3426	20
	<i>Peri-menopausal</i>	5	13	0.2	251	2	264	2
	<i>Post-menopause</i>	18	3769	74	9195	78	12694	77
	<i>Unknown</i>	6	143	3	98	1	241	1
PMH use (at age 55)								
	<i>Ever</i>	16	1703	53	3364	46	5067	48
	<i>Never</i>	16	1326	41	3474	47	4800	45
	<i>Unknown</i>	8	178	6	537	7	715	7
Source of anthropometric data								
	<i>Self-reported</i>	9	3784	74	5909	50	9693	57
	<i>Measurements by trained staff</i>	10	1326	26	5876	50	7202	43
BMI (kg/m <sup>2</sup> ) <sup>a</sup>								
	<i>&lt;25</i>	19	2284	45	5071	43	7355	44

Characteristic	Category	No. of studies	BC cases		Non-cases		Overall	
			N	%	N	%	N	%
	25	19	2737	54	6597	56	9334	55
	Unknown	10	89	2	117	1	206	1
Average time interval between mammography and data collection (months)	6	8	2129	42	4330	37	6459	38
	> 6	11	2981	58	7455	63	10436	62
Mammographic side, view	L - CC	8	831	16	2547	22	3378	20
	R - CC	6	949	19	1830	16	2779	16
	LR average - CC	3	2402	47	2285	19	4687	28
	L - MLO	3	465	9	1978	17	2443	14
	R - MLO	1	447	9	418	4	865	5
	LR average - MLO	4	16	0.3	2727	23	2743	16
Density reading software	Cumulus	15	3814	75	10213	87	14027	83
	Madera	4	1296	25	1572	13	2868	17

BC=breast cancer; BMI=body mass index; CC=cranio-caudal; L=left; MLO=medio-lateral oblique; PMH=postmenopausal hormones; R=right

\* At time of mammography and/or data collection;

\*\* Average time interval for each study given in eTable 2 (range: 0, 5 years).

Table 2

Mammographic Density Measurements by Known Breast Cancer Risk Factors, Mammographic View, and Case Status at Time of Mammography

Risk Factor Categories	N (%)	PD (%) Mean (CI)	Dense Area (cm <sup>2</sup> ) Mean (CI)	Non-Dense Area (cm <sup>2</sup> ) Mean (CI)
<b>Age (years)<sup>*</sup></b>				
< 40	366 (2.2%)	34.2 (30.3, 38.3)	36.8 (31.9, 42.1)	75.1 (66.8, 83.8)
40-49	2794 (16.5%)	28.2 (25.3, 31.4)	33.0 (29.1, 37.1)	89.7 (82.9, 96.8)
50-59	6486 (38.4%)	20.3 (17.9, 22.9)	26.4 (23.0, 30.0)	112.2 (104.8, 119.8)
60-69	5670 (33.6%)	14.9 (12.8, 17.2)	21.3 (18.2, 24.6)	130.2 (122.2, 138.4)
70	1579 (9.3%)	13.0 (11.0, 15.2)	17.3 (14.5, 20.4)	143.0 (134.1, 152.3)
p-value		<0.001	<0.001	<0.001
<b>BMI (kg/m<sup>2</sup>)<sup>†</sup></b>				
< 25	7355 (44.1%)	25.8 (23.2, 28.6)	27.0 (23.6, 30.7)	82.9 (77.1, 89.0)
≥ 25	9334 (55.9%)	14.8 (12.8, 16.9)	23.3 (20.1, 26.7)	144.3 (136.6, 152.3)
p-value		<0.001	<0.001	<0.001
<b>Menopausal status<sup>‡</sup></b>				
Pre- or peri menopausal	3690 (22.2%)	21.5 (19.1, 24.1)	27.1 (23.6, 30.8)	113.5 (106.4, 120.9)
Post-menopausal	12964 (77.8%)	18.4 (16.2, 20.7)	24.1 (20.9, 27.5)	116.3 (109.3, 123.5)
p-value		<0.001	<0.001	0.05
<b>PMH use (at ages 55)<sup>‡</sup></b>				
Never	4800 (48.6%)	14.6 (12.5, 16.9)	20.2 (16.7, 23.9)	129.1 (120.4, 138.2)
Ever	5067 (51.4%)	17.8 (15.5, 20.4)	23.6 (19.9, 27.7)	122.7 (114.2, 131.6)
p-value		<0.001	<0.001	<0.001
<b>Parity<sup>c</sup></b>				
Nulliparous	1781 (10.7%)	22.6 (20.1, 25.2)	29.0 (25.4, 32.9)	109.2 (102.2, 116.4)
Parous	14808 (89.3%)	18.7 (16.5, 21.0)	24.3 (21.1, 27.7)	116.7 (109.8, 123.8)
p-value		<0.001	<0.001	<0.001
<b>Mammographic View<sup>‡</sup></b>				
CC	6051 (35.8%)	17.7 (14.2, 21.5)	25.1 (19.7, 31.1)	122.4 (111.1, 134.2)
MLO	10844 (64.2%)	20.1 (17.3, 23.2)	24.8 (20.6, 29.4)	111.5 (103.2, 120.2)
p-value		0.3	0.9	0.1
<b>Case status<sup>§</sup></b>				
BC case	4530 (37.8%)	24.5 (20.8, 28.4)	30.0 (24.1, 36.4)	108.2 (95.6, 121.5)
Non-case	7439 (62.2%)	19.3 (16.0, 22.8)	24.2 (19.0, 30.1)	117.9 (104.9, 131.7)
p-value		<0.001	<0.001	<0.001

BC=breast cancer; BMI=body mass index; CC=cranio-caudal; MLO= medio-lateral oblique; PMH=postmenopausal hormones

<sup>\*</sup> Adjusted for study<sup>†</sup> Adjusted for study and age<sup>‡</sup> Adjusted for study, age and BMI<sup>§</sup> Restricted to 9 studies that recruited both cases and non-cases and adjusted for study, age and BMI